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Leprosy is a chronic infectious disease caused by an obligate intracellular bacterium 
known as Mycobacterium leprae. Exposure to the bacillus is necessary, but this alone 
does not mean an individual will develop clinical symptoms of the disease. In recent 
years, several genes have been associated with leprosy and the innate immune response 
pathways converge on the main hypothesis that genes are involved in the susceptibility 
for the disease in two distinct steps: for leprosy per se and in the development of the 
different clinical forms. These genes participate in the sensing, main metabolic pathway 
of immune response activation and, subsequently, on the evolution of the disease into 
its clinical forms. The aim of this review is to highlight the role of innate immune response 
in the context of leprosy, stressing their participation in the signaling and targeting pro-
cesses in response to bacillus infection and on the evolution to the clinical forms of the 
disease.
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iNTRODUCTiON
The clinical manifestations of leprosy depend on the interaction between the Mycobacterium leprae 
(M. leprae) and the individual’s immune system (1, 2). The indeterminate form of the disease usually 
appears at the beginning and could evolve into a cure or to any of the clinical forms mentioned below. 
Depending on the immune profile of the host against infection, the disease may present within a 
spectrum of clinical manifestations that vary from a localized form [tuberculoid–tuberculoid (TT)] 
to a disseminated form [lepromatous leprosy (LL)] or one of three intermediate forms (borderline–
tuberculoid; borderline–borderline; borderline–lepromatous) (3).
Although the phenotype of susceptibility to infection by M. leprae is complex and influenced 
by factors of the host and the parasite, and also by environmental conditions, some studies have 
suggested the human genetic factors as important on the acquisition of leprosy and the clinical 
course of disease (4, 5).
PATHOGeN vS. HOST
Although considerable attention has been focused on the development of the adaptive cellular 
immune response during the course of infection, recent investigations of the mechanisms and modu-
lation of innate immunity support the idea that after the indeterminate leprosy, immunoregulatory 
FiGURe 1 | Model of the leprosy spectrum according to Prevedello and Mira (8).
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events should occur, which determine the spectrum of disease. 
The innate immune response, which is the first line of defense 
against M. leprae, is considered a crucial factor in the develop-
ment of a response against the bacillus as it has essential effector 
components to combat the pathogen and is able to direct adap-
tive immunity (6). Most individuals exposed to M. leprae do not 
develop the disease, which may be explained, at least in part, by 
innate resistance provided by the individual’s genetic background 
(1), as demonstrated by recent clinical and epidemiological 
evidence (7). This demonstrates the need of studies investigating 
genetic markers associated with the disease. The spectrum of 
leprosy can be represented in the following model (Figure 1) (8).
An individual when exposed to M. leprae can develop leprosy 
per se under the influence of environmental and genetic factors 
that act on the immune response genes determining efficiency 
in response to infection. If a person develops the disease, it can 
be taken spontaneously, with good immune response induced by 
genetic factors or develop the spectrum of leprosy developing any 
clinical signs: TT, BT, BB, BL, and LL. In the paucibacillary (PB) 
polo (tuberculoid form, TT), activation of Th1 response occurs 
from TCD4+-activating macrophages to release inflammatory 
cytokines and proinflammatory that lead to cell-mediated immu-
nity. While multibacillary (MB) pole is driven by Th2 response, 
which produces anti-inflammatory cytokines, thereby inhibiting 
macrophage microbicidal function of extending the disease to 
a pole with high bacterial load. When an individual is exposed 
to M. leprae, he can develop leprosy per  se by the influence of 
environmental and genetic factors that act on genes from the 
immune system, which determines the response efficiency to 
the infection. If a person develops the disease, it can be taken 
spontaneously, with good immune response induced by genetic 
factors, or develop the spectrum of leprosy developing clinical 
signs: TT, BT, BB, BL, and LL. In the PB polo (tuberculoid form, 
TT), activation of Th1 response occurs from TCD4+-activating 
macrophages releasing inflammatory and proinflammatory 
cytokines that lead to cell-mediated immunity. When MB pole 
is driven by Th2 response, the production of anti-inflammatory 
cytokines will inhibit macrophage microbicidal function, extend-
ing the disease to a pole with high bacterial load.
ReSPONSe iNNATe iMMUNe iN LePROSY
As shown in Figure 1, cell-mediated immunity, phagocytes such 
as macrophages, for example, are activated and have a relevant role 
in innate immunity. In these cells, as well as neutrophils, natural 
killer (NK) cells, and some lymphocytes, are present receptors/
sensors responsible for the activation of innate immunity, such 
as TLRs, VDR, NRAMP1, MRC1, NLRs, MBL, PARK2/PACRG, 
MIC, KIR, cytokines, and CD14. Macrophages are phagocytic 
cells that internalize microorganisms so that they are processed 
and presented to T cells (TCR) by the MHC molecules, as well 
as generate inflammatory responses reactions with the release of 
oxygen and nitrogen species (oxidative bust) and cytokines that 
can activate other cells of the immune system. T cells, in turn, 
release IFN-γ that may activate other immune system cells, which 
are capable of eliminating infected cells. Still, the NRAMP1 gene 
is encoded inside the macrophages, lysosome membrane proteins 
that assist in the process of phagocytosis, acting on ion transport.
The immune cells have cell surface receptors that can promote 
a downstream signaling. Among the surface receptors of innate 
response, there are TLRs, which sense microorganisms and cell 
activation; VDR, which together with the TLR2 participates in 
the activation of the vitamin D-mediated antimicrobial pathway, 
where the vitamin D receptor (VDR) induces the production 
of antimicrobial peptides, such as cathelicidin; MRC with the 
TLR and NOD-2 modulate the autophagy and are involved in 
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host–pathogen interactions; They are important in the sensing 
of mycobacterial peptides; MIC, which are proteins that are 
induced into a state of cellular stress, and can be recognized by 
the NKG2D receptor on the surface of Tγδ lymphocytes, CD8+ αβ 
T lymphocytes, and NK cells that contribute to defend the body 
against infections. Other TLRs receptors are expressed in endo-
some compartments, and there are still receptors present in the 
cytoplasm as NOD2 and RIG1, acting as cytosolic sensors in the 
presence of bacteria and viruses, which might have escaped the 
intracellular internalization. These receptors recognize peptides 
while releasing cytokines and activate the complement inflamma-
tory system and therefore cytokines for adequate inflammatory 
response. The PARK2 acts in the coding process of E3 ubiquitinase 
necessary signaling cascade in certain cellular processes, such 
as NOD2, requiring E3 ubiquitin in NF-kB activation process. 
NK cells recognize MIC expressed in infected cells by NKG2D 
receptor. These cells also express killer cell immunoglobulin-like 
receptor (KIR) molecules for activation and inhibition, as well as 
MHC class I and II, that can recognize peptides and to activate T 
lymphocyte. Markers characteristic of these cells (NK) are CD56 
(Figure 2).
Toll-Like Receptors
Pattern recognition receptors (PRRs), stand out in the innate 
immune response, such as Toll-like receptors are present on 
the cell surface (TLR1, TLR2, TLR4, TLR5, and TLR6), sensing 
microbial components such with lipids, lipoproteins, and proteins 
and also in the cytoplasm (TLR3, TLR7, TLR8, and TLR9) sensing 
microbial and viral species of nucleic acids. The receptors TLR1/2 
are the first to act by promoting cell activation in the presence of 
M. leprae (9, 10). TLR1 recognize lipoproteins present in bacillus 
and promote the differentiation of monocytes in macrophages 
with the release of cytokines, such as IFN-γ and IL-6, and also 
affect the maturation of dendritic cells CD1b+, which can activate 
other effector cells of the immune system, such as T cells, promot-
ing an anti-microbicide activity (11–14) (Figure 3).
Some TLR genes indicate influence of the development of 
mycobacterial diseases because they are able to detect different 
molecules in the bacillus Mycobacterium sp. such as lipomannan, 
lipoarabinomannan, phosphatidylinositol mannoside, laminin, 
LPS, and lipoprotein glycolipids. Once in contact with the TLR 
receptor, a signaling cascade is initiated within the host cell. 
Therefore, alterations in these genes may confer susceptibility/
resistance to leprosy development.
TLR1 N248S polymorphism was studied in a population of 
Bangladesh. The homozygous genotype SS was associated with 
leprosy, but as a protective factor to the development of ENL-
type reactions, and the heterozygous genotype SN was associated 
with protection against leprosy (15). In populations of Brazil, 
case–control and family studies have been performed with 3,162 
individuals showing an association between TLR1 248S and 
leprosy; corroborating the finding that 248S is a susceptibility 
factor for leprosy (16). A case–control study also investigated 
the TLR1-I602S SNP in three distinct populations: New Delhi, 
Kolkata, and Turkey; the authors reached the same conclusions 
thereby demonstrating consistency in the data obtained (17). 
SNPs in other genes of the TLR family have also been investigated 
and their mechanisms of action have been evaluated. One study 
reported the analysis of the TLR1 gene (N602S) and the TLR6 
gene (G1083C), both of which were associated with increased 
IFN-γ levels. The TLR6 (G1083C, C745T) was associated with 
increased IL-2 levels, whereas TLR1 (A1188T) was associated 
with elevated IFN-γ and IL-2 levels (18). Three polymorphisms 
in TLR2 (597C > T, 1350T > C, and a microsatellite marker) were 
analyzed in 431 Ethiopian patients with leprosy and 187 control 
subjects. The microsatellite and the 597C >  T polymorphisms 
both influenced susceptibility to reversal reaction (19). The 
influence of GT microsatellite on the expression of TLR2 was 
measured in 88 leprosy patients, 95 household contacts, and 96 
healthy controls. The allele/genotype of TLR2 microsatellite that 
includes longer GT repeats was associated with low TLR2 mRNA 
expression and high IL-10 production, while that the shorter 
GT repeats were associated with high TLR2 mRNA expression 
and low IL-10 production. High IL-10 producing allele of TLR2 
microsatellite might predispose household contacts to leprosy 
(20). One study on the TLR4 gene (896GA, 1196CT) in an African 
population showed a protective effect of 896GA and 1196TT 
against the development of the leprosy (21). Additionally, this 
study suggested that polymorphisms in the TLR2 gene increase 
the risk of a patient developing reversal reactions; however, this 
polymorphism was not considered a risk factor for the develop-
ment of leprosy per se. These reports on different ethnic groups 
reinforce the idea that Toll-like gene receptors participate in the 
outcome of leprosy.
vitamin D Receptor
TLR2 participates in the activation of the vitamin D-mediated 
antimicrobial pathway, where the VDR induces the production 
of antimicrobial peptides, such as cathelicidin. Polymorphisms in 
the VDR gene can destabilize and/or modify mRNA activity of the 
VDR, resulting in susceptibility to intracellular pathogens (22). 
This vitamin–receptor interaction leads to the suppression of sev-
eral genes, such as interleukin-12 (IL12), colony-stimulating fac-
tor 2 (CSF2) coding granulocyte-macrophage colony-stimulating 
factor (GM-CSF), interferon-gamma (IFNG), and HLA-DRB1, 
inhibiting the production of cytokines and immunoglobulins, 
and lymphocyte proliferation (22–24).
Various polymorphisms in the VDR gene are being investi-
gated for interfering in the mRNA activity and transcription. 
Polymorphisms located near the 3′UTR of the VDR gene (BsmI, 
ApaI, and TaqI) are related to the stability/transcriptional activity 
of VDR mRNA, while a polymorphism located in the translation 
initiation codon, FokI, gives rise to a three amino acid differ-
ence in the VDR length that affects protein function (25). TaqI 
polymorphism in the VDR gene can occur by a substitution of 
a C nucleotide for T, with the loss of a TaqI restriction site in 
the gene, resulting in “T” (wild) and “t” (normal) alleles. A study 
of the population of Mexico associated the TT genotype in the 
VDR gene to the lepromatous form of the disease (26), and also 
in the population of Calcutta, the tt genotype was associated with 
Tuberculoid form leprosy, and the TT genotype was associated 
with Lepromatous form. Heterozygotes with the Tt genotype were 
FiGURe 2 | Signaling between cells that participate in the innate immune response by expressing receptors that interact in the presence of a 
microorganism. (A) Macrophages are phagocytic cells that internalize microorganisms and presented to T cells (TCR). T cells, in turn, release IFN-γ that may 
activate other immune system cells. The NRAMP1 gene is encoded inside the macrophages, lysosomal membrane proteins that assist in the process of 
phagocytosis, acting on ion transport. (B) The immune cells have cell surface receptors that can promote a downstream signaling: TLRs, VDR, MRC, and NOD-2 
(modulate the autophagy). MIC, which are proteins that are induced into a state of cellular stress, can be recognized by the NKG2D receptor on the surface of Tγδ 
lymphocytes, CD8+ αβ T lymphocytes, and natural killer cells (NK) that contribute to defend the body against infections. The PARK2 acts in the coding process of E3 
ubiquitinase necessary signaling cascade in certain cellular processes, such as NOD2, requiring E3 ubiquitin in NF-κB activation process. (C) NK cells recognize 
MIC expressed in infected cells by NKG2D receptor. Abbreviations: TLR, toll-like receptors; MRC, mannose receptor of the C-type lectin; NOD2, nucleotide-binding 
oligomerization domain 2 protein, human; MBL, mannose-binding lectin; PACRG/PARK2, PACRG protein, human/PARK2-coregulated protein, human; MIC, major 
histocompatibility complex class I chain-related genes; KIR, killer cell immunoglobulin-like receptors; IL, interleukins; TNF, tumor necrosis factor; IFN, interferons; 
MHC, major histocompatibility complex; NKG2D, killer cell lectin-like receptor subfamily K; protein; NRAMP, natural resistance-associated macrophage protein; TCR, 
T-cell receptor; MR, mannose receptor; VDR, vitamin D receptor; LPS, lipopolysaccharide; MD2, myeloid differentiation protein-2, human.
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found associated with protection against both leprosy types (23). 
Although a study of the TaqI polymorphism of the VDR gene in 
the population of Minas Gerais, Brazil, did not find significant 
differences, there was a higher frequency of the “t” allele in MB 
compared to PB patients and control individuals, suggesting the 
participation of this allele in developing the most severe form of 
the disease. In this study, a positive association was also observed 
between the tt genotype and a negative Mitsuda test in patients 
with leprosy (22). In the population of Malawi, homozygotes 
with the tt genotype with a silent T > C change in codon 352 of 
the VDR gene are susceptible to the disease (27). These different 
results can be the consequence of the diverse allele and genotype 
frequencies among populations.
Natural Resistance-Associated 
Macrophage Protein 1 Gene
The NRAMP1 gene, located in the chromosome 2q35 region, has 
been reported as one factor responsible for the resistance of mice 
to intracellular pathogens (28). In human cells, it is expressed 
in macrophages and encodes a protein found in lysosomal 
membranes that, in the process of phagocytosis, is recruited for 
phagosome membranes containing pathogens, where it acts as a 
transporter of iron and other divalent ions. Iron is essential for 
biological functions, both for host immune defense and myco-
bacterial growth.
In a study performed in an endemic region of Brazil, there 
were no significant differences in the allelic and genotypic 
FiGURe 3 | Signaling toll-like receptors and interaction with cells of the immune system. (A) TLR1 acts on the differentiation of mononuclear cells into 
macrophages, releasing cytokines, such as IFN-γ and IL-6, whereas when activated, macrophages can release IFN-γ and IL-12. This receiver also operates in the 
maturation of dendritic cells, which become able to present the peptide to lymphocytes T. (B) TLR2 heterodimer with other markers, such as TLR1, TLR6, CD36, 
Dectin1, being able to recognize membrane components of bacteria Gram+ and Gram−. (C) TLR4 forms a complex with MD2 in response to LPS. The marker CD14 
binds to LPS. This LBP–LPS complex binds and releases the TLR–MD2 complex to initiate intracellular signaling.
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frequencies of the NRAMP1 gene in relation to the Mitsuda test 
among patients and household contacts, nor between those with 
the MB and PB forms of the disease. However, individuals with 
a negative lepromin response associated with genotype “22” 
or “23” presented sevenfold and eightfold greater chances of 
developing leprosy, respectively (29). A sib-pair linkage analysis 
between the Mitsuda response and the NRAMP1 gene was done 
among 20 nuclear families with leprosy from Ho Chi Minh City, 
Vietnam. All family subjects were genotyped for several intra-
genic and flanking NRAMP1 markers, leading to the definition 
of a fully informative NRAMP1 haplotype. Significant linkage 
was observed between NRAMP1 and Mitsuda reaction when 
considered either as a quantitative (P < 0.002) or as a categorical 
(P = 0.001) trait. Separate analyses among healthy and affected 
sibs showed evidence for linkage in both subsamples, indicat-
ing that linkage between the Mitsuda reaction and NRAMP1 is 
independent of leprosy status (30).
Hatta et al. determined the association of three polymorphic 
variants (D543N, 3′UTR, and INT4) of the NRAMP1 gene with 
tuberculosis and leprosy in 58 tuberculosis patients, 42 leprosy 
patients and 198 healthy controls from South Sulawesi, Indonesia. 
An association of the INT4 polymorphism was observed with the 
PB type of leprosy (31). In a study conducted in Mali, West Africa, 
a total of 273 patients with leprosy and 201 controls were geno-
typed for NRAMP1 polymorphisms previously associated with 
tuberculosis. No association was found with leprosy per se, but 
the NRAMP13′UTR polymorphism was associated with leprosy 
subtypes (32).
The INT4, D543N, and 3′UTR polymorphisms of NRAMP1 
were also analyzed by in patients with leprosy from Thailand. There 
were no significant difference in the distribution of the genotypes 
and allele frequencies of NRAMP1 polymorphisms between the 
patients and controls (33). The data from seven multi-case leprosy 
families (84 individuals) from French Polynesia were analyzed 
by Roger et al. Nine polymorphic loci and three microsatellite 
markers (D2S104, D2S173, and D2S1471) within NRAMP1 gene 
were typed and the results observed suggest that NRAMP1 is not 
linked to leprosy susceptibility in the French Polynesian families 
tested (34). Another study analyzed polymorphisms of this 
gene to investigate susceptibility for leprosy reactions in Recife, 
Brazil (274C/T, D543N, and 1729 +  55del4 polymorphisms of 
the NRAMP1 gene). The mutant 274TT genotype prevailed in 
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cases without reversal and ENL reactions, suggesting the 274 C/T 
polymorphism of the NRAMP1 gene in determining the suscep-
tibility to reactions in individuals with leprosy (35). Members of 
20 multiplex leprosy families of Vietnam and China (N = 168) 
were genotyped for NRAMP1 alleles and 4 closely linked poly-
morphic markers and the finding showed that the segregation 
of NRAMP1 haplotypes into affected siblings was significantly 
non-random (36).
Mannose Receptor C-Type 1 Gene
The MRC1 gene, located in the chromosome 10p13 region, 
encodes the mannose receptor (MR) in humans. TLRs, the 
nucleotide-binding oligomerization domain (NOD)-2 and MRC1 
genes modulate the autophagy and are involved in host–pathogen 
interactions; they are important in the recognition of mycobacte-
rial peptides and activation of signaling intracellular. A study 
of Vietnamese families analyzed the G396S polymorphism in 
exon 7 of the MRC1 gene and suggested that it is a protective 
factor against leprosy per se and MB leprosy (37). In a Brazilian 
population, the G396-F407 haplotype was considered a risk fac-
tor, while the S396-F407 haplotype was considered a protective 
factor against leprosy (37). Subsequently, Wang et  al. analyzed 
the polymorphism of genetic variants of the MRC1 and IFNG 
genes in Han Chinese patients with leprosy. Although the results 
have not been confirmed, the rs692527 and rs34856358 variants 
of the MRC1 gene were found to be associated with PB leprosy, 
and the rs3138557 variant of the IFNG gene was associated with 
MB leprosy (38).
Cytosolic Receptors: Nucleotide-Binding 
Oligomerization Domain Protein (NOD1 
and NOD2)
Several studies have correlated autophagy with protecting host 
against various intracellular bacteria that use different strategies 
to establish infection. After phagocytosis of the infectious agent, 
different molecules are encoded, such as Toll-like receptors, the 
cytosolic Nod-like receptors (NLRs), and RIG-I-like receptors 
(RLRs), all of which are important in the detection of intracellular 
pathogens. In innate response, the cytosolic sensors belonging to 
the NLR family are able to perceive disturbances in the membrane 
caused by microorganisms and directly recognize MDP mycobac-
terial components. Some NRLs activate NF-kB pathway through 
inflammasome (ASC/Caspase-1), releasing IL-1 and IL-18, while 
others NRLs, such as NOD2 activates NF-kB recruiting RIPK2, 
TRAF, and E3-Ubiquitin, triggering a signaling cascade to activate 
IFN regulatory factor (IRF) and IKKs, and following of P38, JNK, 
ERK MAPK activation, releasing IFNα/β and other proinflam-
matory cytokines. NOD1 is able to direct immune response to 
Gram-negative bacteria, while NOD2 recognizes Gram-negative 
and Gram-positive (14). Among inflammatory cytokines, NOD2 
induce Th17 responses that, in turn, keep the inflammatory 
response. Th17 cells produce IL-17A, IL-17F, IL-21, and IL-22 
as their signature cytokines. IL-17 is correlated with induction of 
proinflammatory programs associated with chemokine secretion 
and neutrophil recruitment that cooperate for mycobacterial 
killing (39). Inflammatory cytokines, such as TNF-α, IL-12, and 
IL-4, are produced after the recognition of the microorganism 
and other components as nitric oxide. Thus, the NOD2 plays an 
important role in the response to microorganisms, helping in the 
recognition, autophagy, and modulating the immune response.
Several studies have correlated NOD2 gene polymorphisms 
to leprosy based on its role in the recognition of mycobacteria 
shortly after signaling mediated by TLRs. Two SNPs in the NOD2 
gene were found to be associated with leprosy in a study of 706 
Han Chinese patients and 1226 healthy controls: rs9302752 
(OR  =  2.28; IC  =  1.70–3.06) and rs7194886 (OR  =  2.25; 
IC = 1.58–3.21) suggesting risk for development of leprosy (40). 
In India, the rs9302752 SNP was investigated in 211 leprosy 
patients and 230 controls, but the results were not considered 
because they were not in Hardy–Weinberg equilibrium (41). The 
study of Zhang (2009) (40) was replicated in a Chinese population 
with tuberculosis (1043 patients vs. 808 controls) for the SNPs: 
rs3135499, rs7194886, rs8057341, and rs9302752 (42). No signifi-
cant differences were found between the genotype frequencies of 
patients and controls, although when they analyzed patients with 
bacteriological confirmation test, the variant rs7194886 showed 
risk to disease (CT/TT vs. CC: OR = 1.35; IC = 1.05–1.72) (42). 
For the NOD2 SNPs found to be associated with leprosy among 
Chinese patients (Zhang, 2009) (40), only the rs9302752 SNP was 
replicated in 474 samples family based from Vietnamese with PB 
and MB leprosy (N = 188 and N = 286, respectively) suggesting 
risk for development of severe form of leprosy (MB) (P = 0.014; 
OR = 1.27; IC = 1.27–1.58) (43). Marques et al. (44) describe the 
results of a validation and replication GWAS study of the Chinese 
(Zhang, 2009) (40) in Brazilians, using a stepwise strategy that 
involved two family-based and three independent case–control 
samples, resulting in 3,614 individuals. Three NOD2 alleles of 
rs8057341 (A allele, Pc = 0.003), rs2111234 (G allele, Pc = 0.031), 
and rs3135499 (C allele, Pc = 0.023) were statistically significant 
in family-based study association, indicating protection to lep-
rosy (44). The replication of the association study between NOD2 
rs8057341 in different populations from Brazil (Rondonópolis, 
Bauru, and Rio de Janeiro) was observed in all case–control 
samples, with the AA genotype conferring resistance to leprosy 
(P =  1.39 ×  10−6; OR =  0.49; IC =  0.36–0.65), but the same 
results were not observed in the family-based study. To obtain 
an overall estimate, all samples (case–control and family-based 
studies) were included to build a summary plot that indicated 
a consensus protective OR value (A allele = 0.80, P = 0.0001), 
confirming allele A of NOD2 rs8057341 as a leprosy resistance 
genetic factor (44). Another study in 933 patients (240 patients 
had reversal reactions and 124 had ENL reactions) of Nepal com-
pared with 101 controls, suggested that NOD2 genetic variants 
are associated with susceptibility to leprosy and the development 
of leprosy reactive states. Four polymorphisms were identified as 
significant (P < 0.05) at the allelic level: (rs12448797: OR 2.18; 
rs2287195: OR 1.51; rs8044354: OR 1.53; and rs1477176: OR 
0.44). Genotypic analysis revealed that these associations with 
ENL were significant for seven SNPs suggesting susceptibil-
ity to developing of type II reactions: (rs2287195, rs8044354, 
rs7194886, rs6500328, rs17312836, rs1861759, and rs1861758) 
(45). Singh et al. examined the occurrence of the three most com-
mon polymorphisms in the NOD2 gene (Arg702Trp, Gly908Arg, 
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and 3020insC) in patients with mycobacterial diseases, but 
significant differences were not observed (46). However, a study 
performed in mononuclear cells of individuals homozygous 
for the 3020insC NOD2 mutation, showed an 80% defective 
cytokine response after stimulation with M. tuberculosis. It was 
also demonstrated that TLR2 and NOD2 mycobacterial ligands 
synergize for the production of inflammatory cytokines, and that 
this synergism is lost in cells lacking either of these receptors. 
The intracellular pathways induced by NOD2 and TLR2 during 
recognition of mycobacterial components synergize, and the 
stimulation of cytokine production by M. tuberculosis is greatly 
impaired in individuals with NOD2 mutations (47). Analysis of 
the sequence variation in the coding regions of the NOD2 gene 
in the 377 African-American from Houston, TX, USA, patients 
with tuberculosis and the 187 control subjects identified 56 
sequence variants. Transition substitutions were more prevalent 
(74.5%) than transversions (25.5%) among these SNPs. Three 
SNPs (Pro268Ser, Arg702Trp, and Ala725Gly) demonstrated 
significant associations with tuberculosis. Minor allele carriers 
(heterozygous and homozygous) of Pro268Ser (OR  =  0.55; 
CI = 0.32–0.94; P = 0.02), and Arg702Trp (OR = 0.27; CI = 0.08–
0.88; P  =  0.01) presented decreased risks for tuberculosis. 
Conversely, the minor allele carrier (heterozygous) of Ala725Gly 
showed an increased risk for tuberculosis disease (OR =  2.16; 
CI = 1.10–4.72; P = 0.03) (48).
Mannose-Binding Lectin
Mannose-binding lectin (MBL) is a soluble protein in the 
serum, which participates in the innate immune response with 
activation of the complement system and opsonization effects. 
This protein binds to several pathogens, allowing complement-
mediated lysis and linkage to membrane of mycobacteria. Many 
studies found an increase in the concentrations of MBL in 
leprosy patients (25, 49, 50).
The genetic analysis of a study developed with a population of 
Nepal (933 leprosy patients), which examined polymorphisms in 
the TNF and MBL genes showed the MBL-G161A variant associ-
ated with protection against LL, and identified a polymorphism 
associated with low MBL levels (homozygosity of MBL-G161A), 
which was associated with a reduced risk of LL when compared 
with TT leprosy (OR =  0.33; CI95% =  0.12–0.85, P =  0.010) 
(25). In Southern Brazil, the polymorphisms at the promoter 
and exon 1 regions of the MBL2 gene were assessed on 264 
patients with leprosy and 214 matched healthy control subjects 
and the results showed a decreased frequency of haplotypes/
genotypes associated with low expression of circulating MBL in 
lepromatous patients when compared with tuberculoid patients. 
The LYPA haplotype related with high expression of MBL was 
associated with susceptibility to leprosy per  se and to progres-
sion to the lepromatous and borderline forms of the disease 
(51). However, another study in the Brazilian population (228 
patients) investigated SNPs of the MBL2 gene and did not find 
significant differences in genotype and allele frequencies (49). 
Finally, a recent study, in the Chinese population, analyzed the 
ficolin-2 (FCN2), mannose-binding lectin (MBL2) and comple-
ment factor H (CFH) genetic variants, which may influence the 
innate immune response to M. leprae (50).
PARK2/PACRG
Parkinson’s disease is characterized by the participation of the 
PARK2 gene and its coregulator PACRG both with a length of 
2 Mb in the chromosome 6q 25.2-q27 region. These genes share 
a regulatory overlap region of about 5 kb, as well as a common 
bidirectional promoter (52). The PARK2 and PACRG genes 
encode proteins that are involved in cellular metabolism of 
ubiquitination. PARK2 encodes parkin and an ubiquitin E3 ligase 
that is involved in the release of polyubiquitinated proteins to the 
proteasome complex. It is suggested that ubiquitin-mediated 
proteolysis has an important role in the control of infections by 
M. leprae.
Four SNPs in the promoter region of the PARK2 gene and 
adjacent to the PACRG gene were found to be associated with 
leprosy in a study of Vietnamese families. Furthermore, in the 
same study using a high-density association scan of both genes, 
19 SNPs between intron 1 of the PARK2 gene and intron 2 of 
the PACRG gene showed evidence of association. The study was 
replicated in the Brazilian population and the findings were con-
firmed (53). Recently, findings reported by Alter et al. confirm 
that the SNPs identified in the promoter region of PARK2/PACRG 
are associated with leprosy in two independent and ethnically 
distinct samples, thus supporting the evidence that these variants 
are risk factors for the development of the disease (54). This study 
evaluated a Vietnamese (198 single cases) and an Indian (364 
cases) population and a control group of northern India (370). 
In the Vietnamese sample, 69 SNPs were associated with leprosy, 
and as expected, two SNPs (rs1040079 and rs9356058) confirmed 
the study carried out by Mira et al. (53). In the case–control study 
in India, three SNPs were also found associated in the Vietnamese 
population (rs6915128, rs10806768, and rs1333955) (54). 
However, analysis of 11 previously indicated risk variants and 
other 2 SNPs (rs13195186 and rs1801474), which are all located 
in the region of PARK2 and PACRG, shows no significant associa-
tion with susceptibility to leprosy per se in the Chinese Population 
(55). In an Indian population, Malhotra et  al. investigated the 
association of six SNPs present in this regulatory region in 286 
leprosy patients and 350 healthy controls and no association with 
leprosy susceptibility was observed (56).
Recently, conducted a mapping of PARK2 and regulatory 
region of the PACRG gene in the north Indian and east Indian-
Orissa population groups, where 11 of the 96 SNPs studied 
showed a strong association with susceptibility to leprosy. The 
results showed 10 SNPs in the region of PARK2: rs9347683 
within the core promoter region of PARK2 gene and SNPs 
rs9347684, rs9346929, rs4709648, rs12215676, rs10806765, 
rs6936373, rs1333957, rs9365492, and rs9355403, located within 
63.8 kb upstream region of the PARK2 gene and only one SNP 
(rs10945859), located 6.67 kb upstream of PACRG gene (57).
Major Histocompatibility Complex Class i 
Chain-Related Genes
Major histocompatibility complex class I chain-related genes A 
(MICA) and B (MICB) are located on chromosome 6 near to the 
HLA-B and HLA-C loci. These genes are highly polymorphic 
producing different MICA and MICB proteins which are induced 
January 2016 | Volume 6 | Article 6588
Mazini et al. Gene Associations with Leprosy
Frontiers in Immunology | www.frontiersin.org
by cellular stress. MICA molecules are recognized by the NKG2D 
receptor on the surface of γδ T lymphocytes, CD8+αβ T lympho-
cytes, and NK cells that contribute to defend the organism against 
infections, including against infection by M. leprae (58, 59).
To determine the association of MICA gene with leprosy and 
its subgroups, Wang et al. examined 69 Southern Chinese patients 
and 112 healthy controls. The frequency of the MICA*A5 allele 
showed a decreasing tendency in the patients with leprosy as 
compared to the controls, but the difference was not significant. 
However, the frequency of the MICA*A5 allele was significantly 
decreased in the MB patients but not in the PB patients (60). A 
study analyzed exon 5 of the MICA gene and intron 1 of MICB in 
families of Southern India who developed PB leprosy and showed 
that MICA*5A 5.1, MICB*CA16 and MICB*CA19 were associ-
ated with the disease (58). The MICA*5A5.1 allele, associated 
with leprosy susceptibility in this much larger study, has a single 
G insertion occurring in a background of five alanine repeats 
causing a frame shift mutation that results in a premature stop 
codon and a truncated transmembrane domain (61).
Recently, our group conducted a study of MICA genes and 
leprosy in a population of southern Brazil showing that the 
MICA*027 allele was decreased in leprosy per  se and in MB 
patients (62). MICA*027 codifies a transmembrane domain, 
A5, related to the normal expression of protein associated with 
protection against, suggesting susceptibility toward leprosy and 
its most severe form.
Killer Cell immunoglobulin-Like Receptor 
Genes
Natural killer cells, which participate in innate and adaptive 
immunity, can be cytotoxic when activated by an exaggerated 
expression of ligands for the activation receptors on the surface of 
target cells. The KIRs expressed on the surface of NK cells interact 
with other cells through specific HLA molecule ligands, transmit-
ting activating or inhibitory signals (63). These receptors possess 
HLA molecules as ligands and can act by activating the cell, 
through activating receptors, or inhibit the cell through inhibi-
tory KIR. The main HLA ligands are divided into three groups: 
C1, C2, and Bw4. The HLA ligands of the C1 Group are character-
ized by presenting serine at position aa77 (AGC) and asparagine 
at position aa80 (AAC) and binding to KIR2DS2, KIR2DL2, and 
KIR2DL3 receptors. The C2 Group is characterized by presenting 
asparagine at position aa77 (AGC) and lysine at position aa80 
(AAA) and binding to the KIR2DS1 and KIR2DL1 receptors. The 
Bw4 Group acts as a ligand to the KIR3DL1 receptor (64).
A study of KIR and their ligands was carried out in a Brazilian 
population comparing leprosy patients with a control group for 
the first time by our group (65). The activating receptor genes 
KIR2DS2 and KIR2DS3 were found at higher frequencies in 
the group of patients with tuberculoid leprosy compared to the 
lepromatous group. The frequency of KIR2DL1 with its ligand 
C2 (HLA-C*02, *04, *05, *06, *07, *15, *17, and *18) was lower 
in the group with the borderline form of the disease, compared 
to the control group and to patients with tuberculoid form. 
Moreover, there was a lower frequency of KIR2DL3 with C1 
(HLA-C*01, *03, *07, *08, *12, *13, *14, and *16) in patients 
with tuberculoid leprosy compared to control individuals, to 
patients with leprosy per se and to the borderline group (65). 
Other study realized with population from Rondonópolis, 
Center-East Brazil, there was a higher frequency of activating 
KIR genes, KIR2DS1, 2DS2, and 3DS1 and your ligands HLA 
in the tuberculoid (TT) group as compared to the LL group. In 
this same study, KIR2DL2/2DL2-C1 was more frequent in the 
patient, TT and LL groups than in the control group. Higher 
frequency of inhibitory pairs it was present in Borderline 
patients when compared to the control group, and a higher 
frequency of activating pairs as compared to the LL group. It 
was realized multivariate analysis and confirmed the associa-
tions and demonstrated that being a female is a protective factor 
against the development of the disease per  se and the more 
severe clinical form (66).
Cytokine Genes
The substitution of a single base in cytokine genes may cause dif-
ferences in the expression of these molecules generating structural 
and functional changes which may influence the host’s response 
to a pathogen. Several authors also described polymorphisms 
of cytokine genes associated with the clinical forms of leprosy 
(67–70).
Brazilian researchers (67, 69–72) found an association 
between the TNF-308A (rs1800629) allele and a protective effect 
against the development of leprosy and results similar were also 
observed in a study in Nepal in 2010 (25). A study performed in 
Rio de Janeiro by Vanderborght et al. (73) observed the relation-
ship between the A allele in the promoter region of the TNF-308 
and a lower bacteriological index (BI), whereas the A allele in 
the promoter region of the TNF-238 (rs361525) was associated 
with a higher BI. However, in Mexican population (74), no 
association was found between TNF-308G/A and leprosy. Some 
studies have suggested a protective role for TNF-α in TT and 
BT patients (75). A study, conducted in an Indian population, 
showed that the frequency of the TNF2 allele (with substitution 
of G > A at position -308, the TNF gene promoter region) was 
significantly associated with LL. A Thai study also showed an 
increase in the frequency of the allele in MB patients, indicat-
ing that this allele in this position induces susceptibility to the 
more severe forms of the disease (33). However, Levee et al. (76) 
found no link between G1M, G2M, KM, IL1B, TNFA (1, 2), and 
TNFA (A, G) and leprosy when performed a linkage study with 
six families of French Polynesian. In the multi-case leprosy family 
study from northeastern of Brazil, the common allele TNFA1 of 
the -308 promoter region polymorphism showed linkage and/or 
association with disease per se, at a high level of significance. Two 
loci transmission disequilibrium testing suggested susceptibility 
to TNFA1/LTA2 and protective to TNFA2/LTA2 haplotypes in 
the class III region, suggesting together the segregation and HLA 
analyses suggest the possibility of more than one susceptibility 
locus to leprosy in the MHC (68).
A study of an Indian population reported the participation of 
variants BAT1-LTA-TNF-BTNL2, as risk factors for the develop-
ment of leprosy (77). According to authors, the combination of 
low T-cell inhibition status of BTNL2, less inhibition of TNF-α 
by BAT1, and low TNF-α expression may provide protection 
from leprosy, which may be stronger in the presence of high 
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TNF-α producer allele genetic background (77). SNPs located 
at BAT1 (HLA-B-associated transcript 1) promoter and 13  kb 
upstream to LTA gene affected the transcription factor binding 
site; hence, the gene expression. BAT1 protein is also known 
to down regulate pro-inflammatory cytokines, such as TNF-α, 
IL-1, and IL-6 (78).
IFN-γ, a cytokine secreted by Th1 CD4+, CD8+ T cells, and NK 
cells, acts in the body’s defense against intracellular pathogens. 
A study in a Brazilian population showed that the T allele at 
position + 874 of the IFNG gene conferred a protective effect to 
leprosy (79), but, Wang et al. (38) found no association between 
IFNG + 874T/A and leprosy in Chinese patients. Nevertheless, the 
variant rs3138557 in the IFNG gene had many CA repeat alleles 
and they observed that the alleles IFNG (10CA), IFNG (13CA), 
and IFNG (15CA) had a higher frequency in patients, especially 
in MB, and that the allele IFNG (17CA) was more frequent in PB 
patients. In Brazilian patients from Amazonas state, there were 
no significant differences between patients and control group. 
Though, the A/A genotype and the allele IFNG (16CA) were 
significantly associated with PB compared to MB patients (80). 
In another population of the same country, Reynard et al. (81) 
observed that a higher frequency of alleles IFNG (15CA), IFNG 
(16CA), and IFNG (17CA) was associated with development of 
leprosy, which indicates that the IFNG gene polymorphism may 
contribute to the course of infection.
Interleukin-6 (IL-6) is a pleiotropic cytokine that plays an 
important role in a wide range of processes, such as immune 
response, acute phase reactions, and hematopoiesis (82). In a 
case–control study (83) was observed a correlation between 
plasma levels of IL-6 and IL6 genotypes in patients with Type-2 
reactions in leprosy. Thus, the identification of genetic factors 
predictive of leprosy reactions could contribute on prevention 
strategies.
Interleukin-12 consists of two covalently linked subunits: p35 
and p40. The effects of IL-12 are mainly controlled by the level of 
transcription of p40 and expression of IL-12R. IL-12 is produced 
quickly after infection and acts as a proinflammatory cytokine 
by inducing IFN-γ production and enhancing the proliferation 
and cytotoxicity of NK and T cells (84). In Indian patients (85), 
subjects with leprosy were less likely to have the 3′UTR genotype 
associated with lower IL-12B expression. In a study in Western 
Mexico (86), it was found that the 1188A/C polymorphism in the 
3′UTR of IL12p40 gene was associated with greater susceptibility 
to LL, without regard to the expression levels of IL-12 p40. On 
the other hand, Jesús Salvador et al. (87) in a study with Mexican 
patients found no significant association between genotype and 
allele frequencies of the 1188A/C polymorphism and LL (87). Liu 
et al. conducted a multiple-stage genetic association study in lep-
rosy patients from China and observed associations implicating 
IL18RAP/IL18R1 and IL12B as susceptibility genes for leprosy 
(88). In another study, Ali et  al. observed that SNP rs2853694 
(A/C at intron 3) in IL12B gene showed a positive association 
with leprosy in Indian patients (89).
Interleukin 10 (IL-10) is a cytokine produced by monocytes 
and activated T cells. It is deeply involved in the regulation of 
inflammatory and immunological reactions. Several polymor-
phisms have been observed in the IL10 gene, including 6–11 CA 
repeats microsatellite polymorphisms, and three point mutations: 
-1082 (G/A) (rs1800896), -819 (C/T) (rs1800871), and -592 
(C/A) (rs1800872) (90).
In Mexican patients (74), no significant difference was found 
in the frequency of IL10-819C allele in patients and controls. 
Nevertheless, in a Brazilian population (91), the IL10-819T allele 
was associated with leprosy in both a case–control study and in 
a meta-analysis. In another Brazilian population (69), where the 
IL10-819TT genotype was significantly higher in patients than 
in healthy controls and the frequency of the IL10-819T SNP 
was greater in PB patients compared to MB or among control 
subjects. However, the genotypes C/C and C/T in the SNP -819 
and C/C and C/A in the -592 SNP were positively associated with 
leprosy in a Colombian population. The haplotypes -819C-592C 
and -1082A-819C-592C showed significant association (92). 
In another study (93) with Brazilian patients, the haplotype 
IL10-3575A/-2849G/-2763C was associated with resistance to 
leprosy and development of more severe forms of the disease, 
and the haplotype IL10-3575T/-2849A/2763C with susceptibil-
ity to LD. Malhotra et al. (94) in a Indian population observed 
that the extended haplotype IL10-3575T/-2849G/-2763C/-
1082A/-819C/-592C conferred resistance to leprosy per  se and 
to development of more severe forms of disease, whereas the 
haplotype IL10-3575T/-2849G/-2763C/-1082A/-819T/-592A 
was associated with the risk of severe form of the disease. A study 
performed in a population of Southern Brazil, Franceschi et al. 
(70) showed a lower frequency of haplotype IL10-1082G/-819C/-
592C in patients with the LL form compared to the control group. 
These studies suggest the involvement of SNPs in the promoter 
region of the IL10 gene in leprosy.
CD14
Some components of mycobacteria, as PGL-1, are recognized by 
TLR1/2 heterodimer, while the LPS, present in abundance in the 
membrane of M. leprae, is transferred by CD14 associated with 
lipopolysaccharide-binding protein (LBP) to the TLR4/MD2 
complex. Thereby, it initiates the signaling for intracellular activa-
tion of NF-κB, with consequent production of interferon (IFN) 
and other cytokines, such as IL-6, TNF-α, and IL-1 (9, 10, 14).
CD14 exists in two forms, its soluble form, sCD14, and mCD14, 
the cell membrane form. sCD14 may be produced by monocytes, 
hepatocytes and endothelial cells and the functional relevance 
of sCD14 is its mediation of bacteria-induced cell activation of 
mCD14 expressing cells (95, 96). In addition to the recognition 
and internalization of LPS, the differentiation of monocytes to 
macrophages is accompanied by regulation of CD14 and data 
suggest that CD14 is essential for TNF-α production, this being 
the most proinflammatory cytokine produced during bacterial 
infection. In combination with the TLR4/MD2 complex, CD14 
recognize LPS, resulting in a proinflammatory immune response 
through TIRAP-MyD88-dependent and TRAM-TRIF depend-
ent TLR4 activation pathways (97, 98). The TLR4 is a signaling 
receptor to LPS and MD2 is a coprotein required to intracellular 
signaling TLR4 (99).
CD14-159 C/T polymorphism was investigated in several 
populations with tuberculosis (95, 100–104). A meta-analysis was 
performed with this marker and -159T allele was associated with 
TABLe 1 | Summary of associations between genes of innate immune response TLR, NOD2, PARK2, PACRG, and leprosy.
Genes Population SNP genotype/(risk allele) Phenotype Compared to OR/(rr) P-value Conclusion
TLR1 Bangladeshi N248S/SS/rs4833095 Per se Controls 1.34 0.012 Susceptibility (14)
TLR1 Bangladeshi N248S/SN/rs4833095 Per se Controls 0.78 0.015 Protection (14)
TLR1 Bangladeshi N248S/SS/rs4833095 ENL Without ENL 0.21 – Protection (14)
TLR1 Indian (New Delhi) I602S/rs5743618 Per se Controls 0.27 1.3 × 10−6 Protection (15)
TLR1 Indian (Kolkata) I602S/SS/rs5743618 Per se Controls 0,40 0.012 Protection (15)
TLR1 Turkish I602S/SS/rs5743618 Per se Controls 0.48 0.004 Protection (15)
TLR1 Brazilian N248S/SS/rs4833095 Per se Controls 1.81 0.004 Susceptibility (16)
TLR2 Ethiopian N199N/rs3804099 RR Controls 5.83 0.001 Susceptibility (19)
TLR4 Ethiopian A299G/rs4986790-T390I/
rs4986791
Per se Controls 0.34/0.16 0.001 Protection (21)
NOD2 Chinese rs9302752 Leprosy Controls 2.28 1.42 × 10−9 Susceptibility (40)
NOD2 Chinese rs7194886 Leprosy Controls 2.25 4.43 × 10−7 Susceptibility (40)
NOD2 Vietnamese rs9302752 Leprosy (family) – 1.17 0.014 Susceptibility (43)
NOD2 Vietnamese rs9302752 MB (family) – 1.30 0.036 Susceptibility (43)
NOD2 Brazilian rs8057341 Leprosy (family) – – 0.003 Protection (44)
NOD2 Brazilian rs2111234 Leprosy (family) – – 0.031 Protection (44)
NOD2 Brazilian rs3135499 Leprosy (family) – – 0.023 Protection (44)
NOD2 Brazilian rs8057341-genotype AA Leprosy Controls 0.49 1.39 × 10−6 Protection (44)
NOD2 Brazilian rs8057341-allele A Leprosy and family Controls 0.80 0.0001 Protection (44)
NOD2 Nepalese rs12448797 Leprosy Controls 3.20 0.016 Susceptibility (45)
NOD2 Nepalese rs2287195 Leprosy Controls 2.29 0.001 Susceptibility (45)
NOD2 Nepalese rs8044354 Leprosy Controls 2.17 0.001 Susceptibility (45)
NOD2 Nepalese rs8043770 Leprosy Controls 2.05 0.004 Susceptibility (45)
NOD2 Nepalese rs13339578 Leprosy Controls 2.19 0.001 Susceptibility (45)
NOD2 Nepalese rs4785225 Leprosy Controls 2.00 0.004 Susceptibility (45)
NOD2 Nepalese rs751271 Leprosy Controls 1.95 0.005 Susceptibility (45)
NOD2 Nepalese rs1477176 Leprosy Controls – 0.0005 Susceptibility (45)
NOD2 Nepalese rs8044354 ENL (MB) without ENL 1.34 0.05 Susceptibility (45)
NOD2 Nepalese rs17312836 ENL (MB) without ENL 1.43 0.039 Susceptibility (45)
NOD2 Nepalese rs1861759 ENL (MB) without ENL 1.42 0.037 Susceptibility (45)
NOD2 Nepalese rs1861758 ENL (MB) without ENL 1.41 0.047 Susceptibility (45)
NOD2 Nepalese rs1131716 LL Controls 2.01 0.013 Susceptibility (45)
NOD2 Nepalese rs2287195 RR (PB) without RR 0.70 0.049 Protection (45)
NOD2 Nepalese rs8043770 RR (PB) without RR 0.68 0.028 Protection (45)
NOD2 Nepalese rs7194886 RR (PB) without RR 0.63 0.018 Protection (45)
NOD2 Nepalese rs1861759 RR (PB) without RR 0.66 0.027 Protection (45)
PARK2 Brazilian PARK2_e01 (-2599) allele T Leprosy Controls – 0.0003 Susceptibility (53)
PARK2 Vietnamese PARK2_e01 (-2599) allele T Leprosy Controls – 0.0006 Susceptibility (53)
PARK2 Brazilian rs1040079 (allele C) Leprosy Controls – 0.001 Susceptibility (53)
PARK2 Vietnamese rs1040079 (allele C) Leprosy Controls – 0.004 Susceptibility (53)
PARK2/
PARCRG
Vietnamese rs1333955 (C) Leprosy Controls – 0.0007 Susceptibility (53)
PARK2/
PARCRG
Brazilian rs1333955 (C) Leprosy Controls – 0.034 Susceptibility (53)
PARK2/
PARCRG
Vietnamese rs1333955 (C) Leprosy (family) – – 0.004 Susceptibility (54)
PARK2/
PARCRG
Indian rs1333955 (C) Leprosy Controls – 0.011 Susceptibility (54)
PARK2/
PARCRG
Vietnamese rs10806768 (A) Leprosy (family) – – 0.012 Susceptibility (54)
PARK2/
PARCRG
Indian rs10806768 (A) Leprosy Controls – 0.0438 Susceptibility (54)
PARK2/
PARCRG
Vietnamese rs6915128 (A) Leprosy (family) – – 0.009 Susceptibility (54)
PARK2/
PARCRG
Indian rs6915128 (A) Leprosy Controls – 0.0455 Susceptibility (54)
PARCG Indian rs10945859 (C) Leprosy Controls 1.32 0.0039 Susceptibility (57)
PARK2 Indian rs9347683 (C) Leprosy Controls 1.31 0.0056 Susceptibility (57)
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(Continued)
Genes Population SNP genotype/(risk allele) Phenotype Compared to OR/(rr) P-value Conclusion
PARK2 Indian rs9347684 (C) Leprosy Controls 1.29 0.0083 Susceptibility (57)
PARK2 Indian rs9346929 (A) Leprosy Controls 1.31 0.0047 Susceptibility (57)
PARK2 Indian rs4709648 (C) Leprosy Controls 1.23 0.055 Susceptibility (57)
PARK2 Indian rs12215676 (C) Leprosy Controls 1.28 0.013 Susceptibility (57)
PARK2 Indian rs10806765 (T) Leprosy Controls 1.32 0.0039 Susceptibility (57)
PARK2 Indian rs6936373 (G) Leprosy Controls 1.26 0.023 Susceptibility (57)
PARK2 Indian rs1333957 (A) Leprosy Controls 1.32 0.0034 Susceptibility (57)
PARK2 Indian rs9365492 (C) Leprosy Controls 1.39 0.00036 Susceptibility (57)
PARK2 Indian rs9355403 (A) Leprosy Controls 1.31 0.0047 Susceptibility (57)
MB, multibacillary; PB, paucibacillary; BB, mid-borderline; BL, borderline lepromatous; BT, borderline tuberculoid; LL, lepromatous leprosy; TT, tuberculoid leprosy; per se, Leprosy 
independent of specific clinical manifestations; ENL, type 2 reactions or erythema nodosum leprosum; RR, Type I or reversal reaction; NR, leprosy who did not have reaction; UTR, 
untranslated region; OR, odds ratio; rr, relative risk; P values; SNPs, single-nucleotide polymorphisms; family, family-based association studies.
TABLe 2 | Summary of associations between genes of innate immune response MBL2, VDR, NRAMP1, MRC1, and leprosy.
Genes Population SNP/genotype/(allele) Phenotype Compared to OR/(rr) P-value Conclusion
MBL2 Nepalese G161A/rs1800450 LL Controls 0.33 0.010 Protection (25)
MBL2 Brazilian LYPAY16577 Leprosy Controls 2.25 0.003 Susceptibility (51)
MBL2 Brazilian LYPAY16577 LL Controls 2.2 0.008 Susceptibility (51)
MBL2 Brazilian LYPAY16577 BB Controls 2.98 0.008 Susceptibility (51)
MBL2 Chinese (GC) rs11003125 MB Controls 0.687 0.031 Protection (50)
MBL2 Chinese (GC) rs7096206 PB Controls 1.416 0.038 Susceptibility (50)
MBL2 Chinese (AA) rs7100749 MB Controls 9.091 0.044 Susceptibility (50)
MBL2 Chinese (GA) rs7100749 PB Controls 0.458 0.004 Protection (50)
MBL2 Chinese (AC) rs11003124 Leprosy Controls 1.357 0.038 Susceptibility (50)
MBL2 Chinese (C) rs11003124 Leprosy Controls 1.401 0.007 Susceptibility (50)
MBL2 Chinese (C) rs11003124 MB Controls 1.458 0.010 Susceptibility (50)
VDR Brazilian TaqI“tt”rs731236 Leprosy MT (−) 13.33 – Susceptibility (22)
VDR Mexican TaqI“TT”rs731236 LL Controls 1.82 0.040 Susceptibility (26)
VDR Indian TaqI“tt”rs731236 TT Controls 3.22 0.001 Susceptibility (23)
VDR Indian TaqI“TT”rs731236 LL Controls 1.67 0.03 Susceptibility (23)
VDR Indian TaqI“Tt”rs731236 LL and TT Controls 0.58 0.008 Protection (23)
VDR Malawi TaqI“tt”rs731236 Leprosy Controls 4.3 0.004 Susceptibility (27)
VDR Nepalese Fok-I/rs2228570 RR Without RR 1.31 0.032 Susceptibility (25)
NRAMP1 Brazilian Genotype 23 Leprosy/MT (−) HC/MT (−) 8.09 – Susceptibility (29)
NRAMP1 Brazilian Genotype 22 and 23 Leprosy/MT (−) HC/MT (−) 7.03 – Susceptibility (29)
NRAMP1 Vietnamese – Mitsuda TDT – 0.002 Susceptibility (30)
NRAMP1 Indonesian INT4/469 + 14 PB Controls 2.975 0.032 Susceptibility (31)
NRAMP1 Malian 3-UTR/1729 + 55del4 MB PB 5.79 0.003 Susceptibility (32)
NRAMP1 Brazilian 274 C/T (TT) ENH Controls – 0.04 Susceptibility (35)
MRC1 Vietnamese G396S/rs1926736 Per se Controls 0.76 0.035 Protection (37)
MRC1 Vietnamese G396S/rs1926736 MB Controls 0.71 0.034 Protection (37)
MRC1 Brazilian G396Srs1926736 Per se Controls 1.34 0.016 Susceptibility (37)
MRC1 Brazilian G396Srs1926736 MB Controls 1.42 0.023 Susceptibility (37)
MRC1 Brazilian L407Frs2437257 Per se Controls 0.75 0.09 Protection (37)
MRC1 Brazilian L407F rs2437257 MB Controls 0.63 0.04 Protection (37)
MRC1 Chinese (CT) rs692527 PB Controls 0.598 0.022 Susceptibility (38)
MRC1 Chinese (TT) rs34856358 PB Controls 1.688 0.022 Susceptibility (38)
MB, multibacillary; PB, paucibacillary; BB, mid-borderline; BL, borderline lepromatous; BT, borderline tuberculoid; LL, lepromatous leprosy; TT, tuberculoid leprosy; per se, leprosy 
independent of specific clinical manifestations; ENL, type 2 reactions or erythema nodosum leprosum; RR, type I or reversal reaction; NR, leprosy who did not have reaction; UTR, 
untranslated region; OR, odds ratio; rr, relative risk; P values; SNPs, single-nucleotide polymorphisms; HC, healthy contacts; MT (−), Negative Mitsuda test.
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risk of development of the disease (OR = 1.27; IC = 1.01–1.61). 
The genotype TT also suggests risk when compared to genotype 
CT and CC (OR = 1.52; IC = 1.11–2.08). The results of this meta-
analysis suggest that CD14 -159C/T polymorphism is associated 
with a predisposition to the development of tuberculosis (105).
Pacheco et al. analyzed the -159C/T polymorphism in patients 
with tuberculosis and a control group of Medellin, Colombia (267 
patients vs. 112 controls) but did not find significant results for this 
polymorphism (95). Another study examined polymorphisms in 
NRAMP -INT4, MBL genes (codons 52, 54, and 57) and CD14 
TABLe 1 | Continued
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-159C/T in patients with tuberculosis in the Caucasian popula-
tion from Poland, and although it has not obtained statistically 
significant results, suggested the involvement of CD14 and MBL 
molecules in the host–mycobacteria interactions on the basis of 
the significant increase in the serum CD14 and MBL in patients 
with tuberculosis (100). The same polymorphism (-159C/T) 
was analyzed in Mexican population, simultaneously with the 
TLR4 expression on the surface of monocytes. Higher levels of 
mCD14/sCD14 and TLR4 were observed in tuberculosis patients 
compared with the control group (P < 0.05). The frequency of 
CD14 -159TT genotype was higher in patients than in control 
group (35.6 vs. 12.3%). Patients who were homozygous for the 
T allele had a significantly higher risk for the development of 
pulmonary tuberculosis (OR = 2.26) (106). In a Korean popula-
tion (274 tuberculosis patients and 422 healthy controls), the 
frequency of -159TT genotypes was found higher in tuberculosis 
patients than in healthy controls. Serum sCD14 levels were higher 
among tuberculosis patients with -159TT genotypes than among 
those with -159CC genotypes and IFN-γ release by PBMCs was 
decreased in subjects with -159TT genotypes (101).
In Chinese population (432 Chinese patients with tuberculosis 
and 404 controls), two positions were analyzed: CD14 -1145 and 
CD14 -159. Both the frequency of allele T in the -159 polymor-
phism (OR = 1.4) and G allele in the -1145 (OR = 1.51) were 
significantly more frequent in cases than in controls (102). This 
study confirms the findings in other populations, such as the 
Americans (107), the Singaporeans (108), and the Chinese (109).
In a case–control study with 698 patients tuberculosis and 404 
controls in the Han Chinese population, SNPs in the promoter 
region do CD14 gene were analyzed: G1619A, T1359G, A1145G, 
and C159T, but statistically significant differences were found 
just for the SNP A1145G (OR = 1.5; 64.00 vs. 53.13%, P < 0.001, 
CI = 1.236–1.849), and SNP C159T (OR = 1.4; P = 0.001, 63.53 
vs. 55.44%, CI =  1.148–1.708) (102). In a Turkish population 
TABLe 3 | Summary of associations between genes of innate immune response MICA, MICB, KIR, TNF, LTA, BAT1, IFNG, and leprosy.
Genes Population SNP allelic group/genotype iD Phenotype Compared to OR/(rr) P-value Conclusion
MICA Chinese MICA*A5 MB Controls (0.52) <0.05 Protection (60)
MICA Indian MICA*5A5.1 Leprosy (family) – – 0.006 Susceptibility (58)
MICA/MICB Indian MICB*CA16 Leprosy (family) – – 0.031 Susceptibility (58)
MICA/MICB Indian MICB*CA19 Leprosy (family) – – 0.021 Susceptibility (58)
MICA/MICB Indian MICB*CA21 Leprosy (family) – – 0.015 Protection (58)
MICA Brazilian MICA*027 Leprosy Controls 0.37 0.02 Protection (62)
MICA Brazilian MICA*027 MB Controls 0.27 0.01 Protection (62)
MICA Brazilian MICA*010 MB Controls 0.35 0.05 Protection (62)
KIR Brazilian KIR2DS3 TT LL 2.72 0.0422 Susceptibility (65)
KIR Brazilian KIR2DL1-C2 BB Controls 0.48 0.0350 Protection (65)
KIR Brazilian KIR2DL1-C2 BB TT 0.30 0.0197 Protection (65)
KIR Brazilian KIR2DL3-C1 TT Controls 0.43 0.0231 Protection (65)
KIR Brazilian KIR3DL2-A3/11 BB Controls 2.04 0.048 Susceptibility (65)
KIR Brazilian KIR2DL1 Leprosy Controls 0.3 0.014 Protection (66)
KIR Brazilian KIR2DL1 BB Controls 0.2 0.014 Protection (66)
KIR Brazilian KIR2DS2-C1 Leprosy Controls 1.4 0.031 Susceptibility (66)
KIR Brazilian KIR2DS2-C1 TT Controls 1.9 0.045 Susceptibility (66)
KIR Brazilian KIR2DL2-C1 Leprosy Controls 2.6 0.024 Susceptibility (66)
KIR Brazilian KIR2DL2-C1 TT Controls 4.1 0.045 Susceptibility (66)
KIR Brazilian KIR2DL2-C1 LL Controls 7.5 0.032 Susceptibility (66)
TNF Thailand TNF-G-308 (A) Leprosy Controls 0.52 0.016 Protection (25)
TNF Thailand TNF-308 (G/A) Leprosy Controls 2.69 0.04 Susceptibility (33)
TNF Thailand TNF-308 (A) MB Controls 2.93 0.04 Susceptibility (33)
TNF Brazilian TNF-308 Per se (family) – – 0.000001 Susceptibility (68)
TNF/LTA Brazilian TNF*1/LTA*2 Per se (family) – – 0.014 Susceptibility (68)
TNF/LTA Brazilian TNF*2/LTA*2 Per se (family) – – 0.001 Protection (68)
BAT1 Indian rs2523504 Leprosy Controls 1.48 2.5 × 106 Susceptibility (77)
LTA Indian rs13192469 Leprosy Controls 1.58 7.2 × 107 Susceptibility (77)
TNF Indian rs1800610 Leprosy Controls 1.45 2.8 × 104 Susceptibility (77)
IFNG Brazilian IFNG + 874(T) rs2430561 Leprosy Controls 0.75 0.005 Protection (79)
IFNG Chinese (10CA) rs3138557 Leprosy Controls 4.202 0.001 Susceptibility (38)
IFNG Chinese (13CA) rs3138557 MB Controls 1.435 0.026 Susceptibility (38)
IFNG Chinese (15CA) rs3138557 MB Controls 1.369 0.007 Susceptibility (38)
IFNG Chinese (17CA) rs3138557 PB Controls 2.239 0.040 Susceptibility (38)
IFNG Brazilian IFNG + 874(AA) PB MB 1.62 0.028 Susceptibility (80)
IFNG Brazilian alleles 5, 6, and 7 TT Controls – 0.013 Susceptibility (81)
MB, multibacillary; PB, paucibacillary; BB, mid-borderline; BL, borderline lepromatous; BT, borderline tuberculoid; LL, lepromatous leprosy; TT, tuberculoid leprosy; per se, Leprosy 
independent of specific clinical manifestations; ENL, type 2 reactions or erythema nodosum leprosum; RR, type I or reversal reaction; NR, leprosy who did not have reaction; UTR, 
untranslated region; OR, odds ratio; rr, relative risk; P values; SNPs, single-nucleotide polymorphisms; Family, family-based association studies.
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TABLe 4 | Summary of associations between genes of interleukins and leprosy.
Genes Population SNP allelic group/genotype iD/haplotype Phenotype Compared to OR/(rr) P-value Conclusion
IL-6 Brazilian (CC) rs1800795 ENL NR 2.41 0.03 Susceptibility (83)
IL-6 Brazilian (CC + CG) rs1800795 ENL NR 3.71 0.005 Susceptibility (83)
IL-6 Brazilian (AA) rs2069832 ENL NR 2.71 0.007 Susceptibility (83)
IL-6 Brazilian (AA + AG) rs2069832 ENL NR 4.00 0.002 Susceptibility (83)
IL-6 Brazilian (GG) rs2069840 ENL NR 0.44 0.03 Protection (83)
IL-6 Brazilian (GG + CG) rs2069840 ENL NR 0.39 0.04 Protection (83)
IL-6 Brazilian (GG) rs2069845 ENL NR 1.92 0.04 Susceptibility (83)
IL-6 Brazilian (GG + AG) rs2069845 ENL NR 2.59 0.045 Susceptibility (83)
IL-12B Indian 3′UTR2.2 Leprosy Controls – 0.001 Protection (85)
IL-12 Mexican 3′UTR 1188 A/C (CC) LL Controls – <0.05 Susceptibility (86)
IL-12 Mexican 3′UTR 1188 A/C (AC) LL Controls – <0.05 Protection (86)
IL12B Chinese rs6871626 Leprosy Controls 0.75 3.95 × 1018 Protection (88)
IL18RAP Chinese rs2058660 Leprosy Controls 1.30 4.57 × 1019 Susceptibility (88)
IL12B Indian (AA vs. AC + CC) rs2853694 Leprosy Controls 1.42 2.6 × 104 Susceptibility (89)
IL-10 Brazilian 819T Leprosy Controls 1.35 0.03 Susceptibility (91)
IL-10 Brazilian 819TT Leprosy Controls 2.64 0.04 Susceptibility (69)
IL-10 Brazilian 819T PB MB 2.28 0.01 Susceptibility (69)
IL-10 Colombian (C/C and C/T) rs1800871 Leprosy Controls 4.34 <0.001 Susceptibility (92)
IL-10 Colombian (C/C and C/A) rs1800872 Leprosy Controls 4.3 <0.001 Susceptibility (92)
IL-10 Colombian Haplotype (819C-519C) Leprosy Controls 4.34 <0.001 Susceptibility (92)
IL-10 Colombian 1082A-819C-592C Leprosy Controls 6.25 <0.001 Susceptibility (92)
IL-10 Brazilian -3575-2849-2763 Leprosy Controls – 0.044 Susceptibility (93)
IL-10 Brazilian -3575A-2849G-2763C Leprosy Controls 0.35 0.005 Protection (93)
IL-10 Indian -819 (TT vs. CT + CC) Leprosy Controls 2.50 <0.005 Susceptibility (94)
IL-10 Indian -819 (CC vs. CT + TT) Leprosy Controls 0.59 0.005 Protection (94)
IL-10 Indian -592 (AA vs. CA + CC) Leprosy Controls 2.43 <0.005 Susceptibility (94)
IL-10 Indian -592 (CC vs. CA + AA) Leprosy Controls 0.60 0.006 Protection (94)
IL-10 Indian -3575T-2849G-2763C-1082A-819C-592C Leprosy Controls 0.58 0.01 Protection (94)
IL-10 Brazilian 1082G-819C-592C LL Controls – 0.02 Protection (70)
MB, multibacillary; PB, paucibacillary; BB, mid-borderline; BL, borderline lepromatous; BB, borderline tuberculoid; LL, lepromatous leprosy; TT, tuberculoid leprosy; per se, leprosy 
independent of specific clinical manifestations; ENL, type 2 reactions or erythema nodosum leprosum; RR, type I or reversal reaction; NR, leprosy who did not have reaction; UTR, 
untranslated region; OR, odds ratio; rr, relative risk; P values; SNPs, single-nucleotide polymorphisms.
the association between the CD14 -159C/T polymorphism and 
tuberculosis (88 patients vs. 116 control subjects) was investi-
gated. There was no significant difference in terms of genotype 
distribution between patients with tuberculosis and controls, but 
serum levels of sCD14 were significantly increased in patients 
with active tuberculosis compared to those with inactive tuber-
culosis and healthy controls (P < 0.001) (104).
The most of associations of innate immune response genes and 
leprosy are summarized in Tables 1–4.
CONCLUSiON
The studies discussed in this review were conducted in diverse 
populations where the incidence of the disease is still high. Although 
the results are consistent with the biological functions of their poly-
morphic genes, many studies present a number of samples down to 
be regarded as true and consistent science. This would need from 
the data shown in the literature, a continuation of research aimed 
at understanding the mechanisms of infection and defense to M. 
leprae with larger number of samples and selected controls (house-
hold contacts), and later of great relevance, replication of the main 
findings in other populations the incidence of the disease remains 
high, giving continuation to the transmission chain.
It will be a great advance to define in the near future, the exact 
polymorphisms that lead to the clinical outcome of leprosy, and 
that make individuals possessing up of resistant form to infection 
or even spontaneous healing. Most findings are also presented in 
a simplified manner without further deepening the understand-
ing of the disease outcome, only indicating a possible influence in 
leprosy, so parking not completing a broader range with concrete 
explanations and proven based on studies standards case– control, 
statistical rules, the local incidence of the disease investigated 
and can sometimes generate false positives, slowing the scientific 
understanding of the disease.
FUTURe PeRSPeCTiveS
Whereas the intervention model for disease control is based on 
early diagnosis, timely treatment of all diagnosed cases, preven-
tion and treatment of disabilities and surveillance of household 
contacts; genetic characterization of gene polymorphisms of 
the immune response of a population that developed leprosy, 
will investigate the influence of these genes in the resistance or 
susceptibility to disease and\or clinical forms, and can generate a 
characteristic genetic profile of patients and controls in this way 
we can redirect drug therapy according to the individual’s profile. 
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